Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004141 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00004141: Completed Phase 2 study, sponsored by University of Chicago.
NCT00004141 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 46 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004141, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one drug with different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus biological therapy in treating patients who have metastatic melanoma.
Interventions
- DRUG Cisplatin
- DRUG dacarbazine
- DRUG Granulocyte-macrophage colony-stimulating factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1998-08 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00004141 record still lists
NCT00004141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00004141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004141 about?
NCT00004141 is a clinical study titled "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one drug with different types of biological therapies ...
What is the current status of trial NCT00004141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 1998-08. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00004141?
The interventions under investigation include: Cisplatin (DRUG), dacarbazine (DRUG), Granulocyte-macrophage colony-stimulating factor (DRUG).
Who is sponsoring clinical trial NCT00004141?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004141's enrollment target sits among peer trials
46 1286th of 2000 higher than 705 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia